The ruling lets Lilly continue comparative advertising for its obesity drugs while Novo Nordisk's challenge fails, intensifying the US GLP-1 marketing battle.

The label expansion moves the talazoparib-enzalutamide pair into earlier use after a trial cut the risk of disease worsening or death by 52%.

The death raises safety questions as BMS and rivals push CAR-T therapy beyond oncology into autoimmune disease.

A rolling submission could make ifetroban the first therapy specifically targeting heart muscle disease in Duchenne muscular dystrophy.

The obesity biotech's listing tests public market appetite for oral GLP-1 assets amid a crowded pipeline.

Chinese licensing and tech-transfer dealmaking keeps scaling, reshaping global drug development economics.

The phased tariff threat on generics adds uncertainty for overseas manufacturers supplying the US market.

Hanmi's domestic obesity launch and its next candidate's WHO naming position the Korean firm in the fast-growing weight-loss market.

Outbound Chinese licensing volume underscores the country's rise as a source of early-stage drug assets.

Analysts question whether the MFN-based international pricing model can be executed, with implications for brand-name drug costs.

Chinese developers are generating a growing share of next-generation obesity assets, drawing multinational partnering interest.

The estimate frames the fiscal stakes of the administration's pricing agreement with drugmakers.

The expanded label broadens tirzepatide's use in Korea beyond weight and diabetes management.

The cut reflects mounting price competition in the US obesity market.

Amgen's pipeline update keeps it in the race for next-generation obesity therapies beyond current market leaders.

The trial readout reaffirms efficacy for Novo's obesity portfolio amid intensifying competition.

The ESMO readout supports a possible FDA accelerated approval pathway for Xencor's kidney cancer bispecific.

Investors see Viking's oral obesity data as pivotal to its competitive position against injected GLP-1s.